CATALYST PHARMACEUTICALS, INC. 4

Insider Daniel J. Curran had 58,115 stock options and 5,468 RSUs in Catalyst Pharmaceuticals, Inc. cashed out for merger consideration at an implied $31.50 per share value on July 15, 2026.

On July 15, 2026, in connection with the closing of a merger at a $31.50 per share cash consideration, insider Daniel J. Curran had all of his outstanding equity awards in Catalyst Pharmaceuticals, Inc. cancelled and cashed out. Two tranches of stock options to purchase common stock—40,000 options with a $21.12 exercise price and 18,115 options with a $22.77 exercise price—were terminated and converted into cash equal to the intrinsic value of each grant (the $31.50 merger price minus the respective exercise price) multiplied by the number of underlying shares, implying cash proceeds of roughly $416,000 and $159,000, respectively. In addition, 5,468 restricted stock units were fully vested and similarly cancelled for cash based on the $31.50 merger price, for proceeds of about $172,000. Following these cash‑out transactions, Curran no longer held equity in the company, as all reported options and RSUs were extinguished in exchange for cash consideration at closing.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000172

Alert Tier

6